Quick Summary

Prothrombin induced by vitamin K absence-II (PIVKA-II) was reported as a diagnosis and prognosis marker for hepatocellular carcinoma (HCC). This prospective study aims to comparatively verify Elecsys PIVKA-II and conventional Lumipulse PIVKA-II from the serum samples of patients with unresectable HCC undergoing systemic therapy.